It is known that CFTR (cystic fibrosis transmembrane conductance regulator) modulators improve lung diseases associated with cystic fibrosis (CF). However, the effects of CFTR therapies on structural changes in the lungs of CF patients are unclear. US researchers therefore wanted to determine the effects on clinical parameters and structural lung disease, as measured by changes in chest CT scans, in people with CF.
This content is machine-translated. Please contact us if you need professional translation services.
Publikation
- InFo PNEUMOLOGIE & ALLERGOLOGIE
